Redeye briefly comments on Isofol setting the final terms for the exercise of its TO1 warrants issued in connection with the oversubscribed 2025 rights issue. The exercise price has been set at SEK0.48 per share, and full exercise could raise approximately SEK19m, corresponding to a dilution of about 12.4%. While the proceeds are relatively modest, we view the warrants as providing additional financial flexibility as the company advances the ongoing phase Ib/II study with arfolitixorin, supported by encouraging participation signals from key shareholders and partner Solasia Pharma.
LÄS MER
